Abstract
Abstract Objective The 2016 update to the World Health Organization (WHO) states that oligoastrocytoma (OA) should be classified as either oligodendroglioma or astrocytoma based on molecular biomarkers. We examined the survival patterns of patients diagnosed with OA in the Surveillance, Epidemiology and End Results (SEER) registry in the context of this revised scheme. Methods We used data from the SEER database (1999–2010) to identify patients diagnosed with WHO grade II astrocytoma (A2, n = 4113), WHO grade II oligodendroglioma (O2, n = 2378), and oligoastrocytoma (OA, n = 1505). Survival comparison was performed using Kaplan-Meier analysis and multivariate Cox proportional hazards analysis. Results Similar to O2 patients, gross total resection (GTR) was not associated with improved survival in OA patients. In contrast, GTR is associated with improved survival in A2 patients. For OA patients who did not undergo surgery or radiation therapy (RT), those with tumors Conclusions Distinct survival patterns were observed in SEER OA patients with tumors
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
